# Michael Onuscheck

> Michael Onuscheck is CEO and Chairman of Presidio Medical, a San Mateo clinical-stage neuromodulation company developing an ultra-low-frequency waveform platform aimed at chronic pain. He joined in September 2021 after two years on the board, returning to neuromodulation after leading Alcon's global businesses and, earlier, Boston Scientific's Neuromodulation division.

- **Role:** CEO and Chairman at Presidio Medical, Inc.
- **Organizations:** Presidio Medical, Inc., Alcon, Boston Scientific, Advanced Bionics, Medtronic, Pfizer
- **Nationality:** American
- **Education:** B.A., Business Administration and Psychology, Washington & Jefferson College
- **Known for:** Led commercial launch of the Precision Spinal Cord Stimulation System at Boston Scientific, Ran Boston Scientific's Neuromodulation division as SVP and President, Executive Committee Member at Alcon leading Global Businesses and Innovation

## Career timeline

- **1989** — Graduates from Washington & Jefferson College
- **1990s** — Sales and marketing roles at Pfizer
- **1990s-2001** — Commercial management roles at Medtronic in spinal reconstructive surgery and stereotactic image-guided surgery
- **2001-2004** — Advanced Bionics — leadership roles including President, Pain Management
- **2004-2015** — Boston Scientific — roles including VP Sales & Marketing (Pain Management), SVP & President Neuromodulation (2008-2011), SVP & President EMEA (2011-2015)
- **2015** — Joins Alcon as President and GM of Global Surgical business
- **2018** — Named Alcon Executive Committee Member and President, Global Businesses and Innovation
- **2019** — Joins Presidio Medical board as independent director
- **2021-09** — Appointed CEO and Chairman of Presidio Medical
- **2023-06** — Presidio Medical closes $72M Series C led by Deerfield
- **2024** — Speaker at Wilson Sonsini's Medical Device & Digital Health Conference

## Achievements

- Led commercial launch of the Precision Spinal Cord Stimulation System at Boston Scientific
- Ran Boston Scientific's Neuromodulation division as SVP and President
- Executive Committee Member at Alcon leading Global Businesses and Innovation
- Closed Presidio Medical's $72M Series C round in June 2023
- Secured FDA IDE approval for ultra-low-frequency neuromodulation clinical study

## Latest updates

- **2023-06** — Closed $72M Series C led by Deerfield Management
- **2024-03** — Featured speaker at Wilson Sonsini Medical Device & Digital Health Conference

## Links

- Website: https://presidiomedical.com
- LinkedIn: https://www.linkedin.com/in/michael-onuscheck-292a524b/
- Twitter/X: https://twitter.com/PresidioMedical

---

Profile page: https://yespress.io/michael-onuscheck
Published by YesPress — https://yespress.io
Last updated: 2026-07-09